Literature DB >> 27807322

[Influence of HMGB1/MAPK/m-TOR signaling pathway on cell autophagy and chemotherapy resistance in K562 cells].

Liying Liu1, Fei Gao1, Yanqiong Ye2, Zhiheng Chen3, Yunpeng Dai1, Ping Zhao1, Guotao Guan1, Mingyi Zhao3.   

Abstract

OBJECTIVE: To observe the effect of high-mobility group box 1 (HMGB1) on autophagy and chemotherapy resistance in human leukemiacell line (K562) cells, and to explore the underlying mechanisms.

Methods: The K562 cells were cultured in vitro and divided into 6 groups: a chemotherapeutic group, a chemotherapeutic control group, a HMGB1 preconditioning group, a HMGB1 preconditioning control group, a HMGB1 siRNA group and a siRNA control group. The chemotherapeutic group was further divided into a vincristine (VCR) group, an etoposide (VP-16) group, a cytosine arabinoside (Ara-C) group, a adriamycin (ADM) group and a arsenic trioxide (As2O3) group. The cell activity was evaluated by cell counting kit-8. The protein levels of HMGB1, microtubule-associate protein1light chain3 (LC3), AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (m-TOR) were determined by Western blotting. The level of serum HMGB1 was evaluated by enzyme-linked immunosorbent assay (ELISA). The autophagy was examined by monodansylcadaverine staining and observed under transmission electron microscopy.

Results: Compared with the control group, the cell activity was significantly decreased and the level of serum HMGB1 was significantly increased in the chemotherapeutic (VCR, VP-16, Ara-C, ADM and As2O3) groups (all P<0.05). Compared with the control group, the cell activity and the level of serum HMGB1 were significantly increased in the HMGB1 preconditioning group (both P<0.05). Compared with the siRNA control group, the cell activity and the level of serum HMGB1 were significantly decreased in the HMGB1 siRNA group (both P<0.05). Compared with the control group, the expression of LC3-II and the formation of autophagic bodies were increased in the HMGB1 preconditioning group (both P<0.05), the p-AMPK expression was increased and p-mTOR expression was decreased (both P<0.05).

Conclusion: HMGB1 can increase the autophagy and promote chemotherapy resistance through the pathway of AMPK/m-TOR in K562 cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27807322     DOI: 10.11817/j.issn.1672-7347.2016.10.002

Source DB:  PubMed          Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-7347


  6 in total

1.  AICAR suppresses cell proliferation and synergizes with decitabine in myelodysplastic syndrome via DNA damage induction.

Authors:  Jin Liu; Long Liang; Xin Li; Yuan Liang Peng; Ji Zhang; Xiao Long Wang; Jing Liu; Ling Nie
Journal:  Biotechnol Lett       Date:  2021-03-31       Impact factor: 2.461

2.  miR-451 on Myocardial Ischemia-Reperfusion in Rats by Regulating AMPK Signaling Pathway.

Authors:  Yulin Guo; Jie Gao; Yan Liu; Xitao Zhang; Xiangguang An; Jian Zhou; Pixiong Su
Journal:  Biomed Res Int       Date:  2021-07-06       Impact factor: 3.411

3.  Gefitinib Inhibits Bleomycin-Induced Pulmonary Fibrosis via Alleviating the Oxidative Damage in Mice.

Authors:  Li Li; Lin Cai; Linxin Zheng; Yujie Hu; Weifeng Yuan; Zhenhui Guo; Weifeng Li
Journal:  Oxid Med Cell Longev       Date:  2018-04-12       Impact factor: 6.543

Review 4.  High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies.

Authors:  Shunling Yuan; Zhaoping Liu; Zhenru Xu; Jing Liu; Ji Zhang
Journal:  J Hematol Oncol       Date:  2020-07-13       Impact factor: 17.388

5.  The effect of HMGB1 on the clinicopathological and prognostic features of cervical cancer.

Authors:  Pan Li; Mengfei Xu; Hongbing Cai; Niresh Thapa; Can He; Ziye Song
Journal:  Biosci Rep       Date:  2019-05-02       Impact factor: 3.840

6.  Extracellular HMGB1 interacts with RAGE and promotes chemoresistance in acute leukemia cells.

Authors:  Weixin Lai; Xinyu Li; Qian Kong; Han Chen; Yunyao Li; Lu-Hong Xu; Jianpei Fang
Journal:  Cancer Cell Int       Date:  2021-12-21       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.